



Study
Just Completed
SaltStable LS
Advanced™ Proven
to Deliver **8 Drugs**
Simultaneously*!
Contact Us for Details

New SaltStable LS Advanced™ Transdermal Study

The Most
**Scientifically
Advanced**
Product on
the Market
Today!

ADDITIONAL FORMULAS TESTED

Baclofen	2%
Bupivacaine HCl	1%
Cyclobenzaprine HCl	2%
Diclofenac Na	5%
Gabapentin	6%
Ibuprofen	3%
Ketamine HCl	10%
Pentoxifylline	3%
SaltStable LS Advanced™	q.s. 100%

Diclofenac Na	5%
Ibuprofen	3%
Pentoxifylline	3%
Verapamil HCl	10%
SaltStable LS Advanced™	q.s. 100%

STUDY

Evaluation of the Percutaneous Absorption of Ketamine HCl + Gabapentin + Clonidine HCl + Baclofen, In SaltStable LS Advanced™, Into Human Skin, In Vitro, Using the Franz Skin Finite Dose Model

Using Humco's SaltStable LS Advanced™ the study was designed to evaluate the percutaneous absorption pharmacokinetics of ketamine HCl, gabapentin, clonidine HCl and baclofen. Absorption was measured in human epidermal cultures, in vitro, using the finite dose technique and Franz Diffusion Cells. The four drugs were selected due to their frequent use in compounding topical pain formulations along with compounding multiple actives in one formulation.

TESTED FORMULA

Ketamine HCl	5%
Gabapentin	10%
Clonidine HCl	0.2%
Baclofen	2%
SaltStable LS Advanced™	qs 100%

The formula was tested on standardized sections with Salt Stable LS, transdermal compounding base, for the percutaneous absorption of ketamine HCl, gabapentin, clonidine HCl and baclofen over a 48-hour dose period. At pre-selected times after dose application, the dermal receptor solution was removed in its entirety, replaced with fresh receptor solution, and an aliquot saved for subsequent analysis. High Performance Liquid Chromatography (HPLC) analyzed the samples.

RESULTS

Humco's SaltStable LS Advanced™ is proven to deliver multiple drugs beyond the stratum corneum, simultaneously into and through the human skin after a single dose in the base. The absorption profiles indicate a rapid penetration to a peak flux for gabapentin occurring at approximately 4 hours after dose application, and for baclofen occurring at approximately 8 hours after dose application. The absorption profiles indicate a steady penetration to a peak flux for ketamine HCl occurring at approximately 12 hours after dose application, and for clonidine HCl occurring at approximately 32 hours after dose application.